← Human Trials & Peer-Reviewed Studies
The influence of methylene blue infusion on cytokine levels during severe sepsis
Plain-language guide to PMID 12500513 (2002): double-blind randomized controlled trial study of Methylene blue (non-peptide stack partner).
Key Facts
- PMID
- 12500513
- Journal
- Anaesthesia and intensive care
- Year
- 2002
- Study type
- Randomized Controlled Trial
- Authors
- Memis D et al. (5 authors)
- DOI
- 10.1177/0310057X0203000606
- Registered trial
- NCT06306001, NCT03120637
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Methylene blue (non-peptide stack partner).
The aim of their study was to assess the effect of methylene blue infusion on plasma levels of cytokines in severe sepsis.
Why It Was Studied
The researchers evaluated haemodynamic parameters (mean arterial pressure, heart rate), blood gases, methaemoglobin levels, and biochemical parameters at the same time.
Who Took Part
By PubMed's age tags, the people studied were adults, middle-aged adults, older adults and people over 80, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
Because people in this Methylene blue (non-peptide stack partner) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the participants and researchers unaware of who received Methylene blue (non-peptide stack partner).
A placebo (an inactive look-alike) gave the Methylene blue (non-peptide stack partner) group a baseline to be compared against.
Plasma concentrations of tumour necrosis factor-alpha, interleukin-1, interleukin-2 receptor, interleukin-6, interleukin-8 were measured by sensitive immunoassays at basal (15 min before start of the study), immediately after, and at 24 and 48 hours after methylene blue infusion.
What Was Measured
The researchers evaluated haemodynamic parameters (mean arterial pressure, heart rate), blood gases, methaemoglobin levels, and biochemical parameters at the same time.
Topics PubMed links to this paper include Cyclic GMP, Cytokines, Enzyme Inhibitors, Hemodynamics, Interleukins, Methemoglobin and Methylene Blue.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Methylene blue (non-peptide stack partner).
The publication is from 2002 (Anaesthesia and intensive care), a journal based in United States.
More context: the Methylene blue (non-peptide stack partner) compound page.
Our Notes on the Compound
Methylene blue (non-peptide stack partner): Described as an electron cycler, not just a dye.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.